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Comparison of Gene Delivery
Techniques for Therapeutic Angiogenesis
Ultrasound-Mediated Destruction of Carrier
Microbubbles Versus Direct Intramuscular Injection
Jeremy Kobulnik, MD,* Michael A. Kuliszewski, BSC,* Duncan J. Stewart, MD,*
Jonathan R. Lindner, MD,† Howard Leong-Poi, MD*
Toronto, Ontario, Canada; and Portland, Oregon
Objectives This study was designed to compare the efficacy of angiogenic gene delivery by ultrasound-mediated (UM) de-
struction of intravenous carrier microbubbles to direct intramuscular (IM) injections.
Background Current trials of gene therapy for angiogenesis remain limited by suboptimal, invasive delivery techniques.
Methods Hind-limb ischemia was produced by iliac artery ligation in 99 rats. In 32 rats, UM delivery of green fluorescent
protein (GFP)/vascular endothelial growth factor-165 (VEGF165) plasmid deoxyribonucleic acid was performed.
Thirty-five animals received IM injections of VEGF165/GFP plasmid. Remaining rats received no treatment. Before
delivery (day 14 after ligation) and at days 17, 21, and 28 and week 8 after ligation, microvascular blood vol-
ume and microvascular blood flow to the proximal hind limbs were assessed by contrast-enhanced ultrasound
(n  8 per group). Total transfection was assessed by reverse transcriptase–polymerase chain reaction, and lo-
calization of transfection was determined by immunohistochemistry.
Results By day 28, both IM and UM delivery of VEGF165 produced significant increases in microvascular blood volume
and microvascular blood flow. Whereas increases in microvascular blood volume were similar between treat-
ment groups, microvascular blood flow was greater (p  0.005) in UM-treated animals as compared with IM-
treated animals, persisting to week 8. The VEGF165/GFP messenger ribonucleic acid expression was greater
(p  0.05) for IM-treated animals. A strong GFP signal was detected for both groups and was localized to focal
perivascular regions and myocytes around injection sites for IM and to the vascular endothelium of arterioles/
capillaries in a wider distribution for UM delivery.
Conclusions Despite lower transfection levels, UM delivery of VEGF165 is as effective as IM injections. The UM delivery results
in directed vascular transfection over a wider distribution, which may account for the more efficient
angiogenesis. (J Am Coll Cardiol 2009;54:1735–42) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.023e
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hver the past 2 decades, there have been numerous clinical
rials designed to promote new vessel growth by pro-
ngiogenic gene delivery in patients with refractory symp-
omatic coronary artery disease and peripheral arterial dis-
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ccepted July 6, 2009.ase (1). Whereas initial small open-labeled trials yielded
romising results, subsequent larger double-blind, random-
zed, placebo-controlled, clinical trials have failed to show
ignificant clinical benefits (2,3). The largely disappointing
esults of clinical trials of therapeutic angiogenesis may in
art be explained by suboptimal delivery techniques (4,5),
nvolving either intra-arterial or direct intramuscular
njection.
Intra-arterial delivery of genes is largely ineffective and
an result in systemic delivery (6). Whereas intramuscular
elivery is more effective (6), this strategy remains limited by
he inability to target specific cell types, the localized nature
f transfection in proximity to injection sites, and the
mpracticality for repeated delivery into tissues such as the
eart. The ability to noninvasively deliver genetic material
o specific target tissues, such as the vascular endothelium,
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Ultrasound-Mediated Versus IM Gene Delivery for Angiogenesis October 27, 2009:1735–42in a controlled manner would be
an important step toward a safe
and effective pro-angiogenic
gene therapy.
Ultrasound-mediated (UM)
destruction of intravenously ad-
ministered deoxyribonucleic acid
(DNA)-bearing carrier micro-
bubbles during their microcircu-
latory transit has been used to
amplify transfection of reporter
plasmid DNA to skeletal (7) and
cardiac muscle (8). We have pre-
viously demonstrated that UM
destruction of microbubbles bear-
ing vascular endothelial growth
factor-165 (VEGF165) plasmid
DNA results in enhanced trans-
fection of the vascular endothe-
lium and improved tissue perfu-
sion in chronically ischemic
skeletal muscle (9). The aim of our
present study was to compare gene
elivery by ultrasonic destruction of intravenous VEGF165
lasmid-bearing microbubbles to direct intramuscular (IM)
njections, for therapeutic angiogenesis. The study was de-
igned to test whether in the context of reduced limb blood
ow, this vascular-based strategy would be superior to stan-
ard, but more invasive, direct IM injections, and whether the
eovascularization response could be explained by the differ-
nces in the localization of gene transfection between delivery
ethods.
ethods
icrobubble and DNA preparation. Plasmid DNA was
harge-coupled to cationic lipid microbubbles as previously
escribed (7,9). For perfusion imaging, lipid-shelled deca-
uorobutane microbubbles were used. Microbubble concen-
rations were determined using a Coulter Multisizer IIe
Beckman Coulter, Fullerton, California). A bicistronic
lasmid vector was constructed for the cotransfection of
oth enhanced green fluorescent protein (GFP) and human
EGF165 (9).
nimal preparation. The study protocol was approved by
he Animal Care and Use Committee at St. Michael’s
ospital Research Centre, University of Toronto. Proximal
ind-limb ischemia was produced in 99 Sprague-Dawley
ats. Rats were anesthetized with intraperitoneal injection of
etamine hydrochloride (10 mg·kg1) and xylazine (8
g·kg1). Under sterile conditions, the left common iliac
rtery and small proximal branches were exposed and ligated
ith 4-0 sutures. The incision was closed in layers and
nimals were recovered.
erfusion imaging. Contrast-enhanced ultrasound (CEU)
Abbreviations
and Acronyms
CEU  contrast-enhanced
ultrasound
DNA  deoxyribonucleic
acid
GFP  green fluorescent
protein
FMA  fluorescent
microangiography
IM  intramuscular
MBF  microvascular blood
flow
MBV  microvascular
blood volume
PBS  phosphate buffered
saline
RNA  ribonucleic acid
UM  ultrasound-mediated
VEGF  vascular
endothelial growth factormaging of the proximal hind-limb adductor muscles was aerformed as previously described (9), to obtain perfusion
ata on microvascular blood volume (MBV), velocity, and
icrovascular blood flow (MBF) (9).
ene delivery. For ultrasound-mediated (UM) gene deliv-
ry, cationic microbubbles (1 109) coupled with 500 g of
omplementary DNA were infused intravenously during
ltrasound transmission (Sonos 5500, Philips Healthcare,
ndover, Massachusetts) at 1.3 MHz and a transmit power
f 0.9 W, using a pulsing interval of 5 s (9). At these
ettings, peak negative acoustic pressure by needle hydro-
hone (PVDF-Z44, Specialty Engineering Associates,
unnyvale, California) was calculated to be –2,100 kPa
assuming a tissue attenuation coefficient of 0.3 dB/cm/
Hz, at tissue depth of 1 cm). For IM gene delivery, 500
g of VEGF165/GFP plasmid DNA was injected directly
nto the ischemic hind-limb adductor muscle at 5 evenly
paced sites spanning the length and width of the proximal
dductor muscle, using a 24-gauge needle. This resulted in
mean distance between injection sites of 5 mm. In a subset
f animals (n 3), plasmid DNA was admixed with 10-m
ed fluorescent beads (100,000 beads/injection) before IM
elivery, to allow for localization of transfection in relation
o site of IM injection.
luorescent microangiography. Immediately before sacri-
ce, the distal hind-limbs were flushed with heparinized
aline via an abdominal aortic cannula. A 10% solution of
uorescent microspheres (0.2 m) (Sigma-Aldrich, St.
ouis, Missouri) mixed with a 1% solution of low melting
oint agarose at 45oC was injected at constant rate into the
ortic cannula until seen on venous return. The animal was
uthanized and placed in an ice bath to facilitate cooling and
olidification of the casting agent. Hind-limb tissue was placed
n 10% buffered formalin, sectioned (200 m) using a vi-
ratome and visualized under confocal microscopy. A series of
tacked images (4-m slices) were taken and the middle 25
lices (100-m total thickness) were projected to quantify the
essel density using automated software (IPTK analysis soft-
are, Reindeer Graphics Inc., Asheville, North Carolina) (9).
mmunohistochemistry. In vivo transfection efficacy and
patial localization was determined using immunohisto-
hemistry. Explanted tissue was cryoembedded in optical
utting temperature compound (Sakura Finetek Japan, To-
yo, Japan) and stored at –80oC. Cryo-blocks were sec-
ioned (15-m thick) every 25 m and rehydrated in
hosphate buffered saline (PBS), fixed in 2% paraformalde-
yde (Sigma-Aldrich) in PBS, and washed with PBS. Cell
urface antigens were identified using mouse antihuman
D31 (Alpha Diagnostics Inc., San Antonio, Texas),
ouse antihuman Tie-2 (Clone Ab33, Upstate Biotechnol-
gy, Milford, Massachusetts), and mouse antihuman
lpha-actin (Sigma-Aldrich). The presence of antibody was
onfirmed by exposure to a phycoerythrin conjugated sec-
ndary antibody. TO-PRO-3 (Invitrogen, Burlington, On-
ario, Canada) was used as a nuclear marker.
To better assess regional distribution, tissue was prepared
nd sectioned as described earlier and visualized under
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October 27, 2009:1735–42 Ultrasound-Mediated Versus IM Gene Delivery for Angiogenesisuorescent microscopy for VEGF/GFP signal. Hind-limb
keletal muscle was divided into a 10  10 grid (using 20
igh power fields) and every other field was scored for the
resence of GFP signal (checkerboard grid with a total of 25
cored fields). Fields were deemed positive if clear GFP
ignal was detectable, and the number of positive fields (out
f 25) was recorded.
To assess spatial localization in relation to site of IM
njection, tissue was prepared and sectioned as described
reviously. Sections were visualized under low-magnification
onfocal microscopy and injection sites were identified by
he presence of 10-m red fluorescent beads, which re-
ained adjacent to the site of IM injection. Four adjacent
ow power fields were taken with the same confocal settings
nd recompiled to illustrate one contiguous image of GFP
ransfection in relation to the red fluorescent beads that
ark the injection site.
everse transcriptase–polymerase chain reaction. Semi-
uantitative real-time reverse transcriptase–polymerase
hain reaction for exogenous VEGF165/GFP transcript was
erformed on hind-limb tissue, as previously described (9).
riefly, tissue samples were harvested, flash frozen in liquid
itrogen, and stored at –80oC until processing. Messenger
ibonucleic acid (RNA) was isolated using the Aurum total
NA kit (Bio-Rad Laboratories, Mississauga, Ontario), which
tilizes deoxyribonuclease to ensure no plasmid DNA contam-
nation in the final product. Because, a bicistronic vector was
sed to deliver VEGF165/GFP, the following primers were
sed to assay for exogenous transgene expression: forward
=-ACGTAAACGGCCACAAGTTC-3= and reverse 5=-
AGTCGTGCTGCTTCATGTG-3=.
xperimental protocol. Contrast-enhanced ultrasound
erfusion imaging of the ischemic and contralateral control
ind-limb adductor muscles was performed 14 days after
igation. Gene delivery was then performed, according to
ssigned treatment groups: group 1—intramuscular injec-
ion of VEGF165/GFP plasmid (IM); group 2—ultrasound
ediated VEGF165/GFP plasmid microbubble delivery
UM); and group 3—control group, no treatment (n 32 per
roup). Then, CEU imaging was performed at days 17, 21,
nd 28 and 8 weeks after ligation (n  8 per group). In 4 rats
er group (days 28 and week 8), FMA was performed before
acrifice. An additional 3 rats underwent intramuscular injec-
ions of VEGF165/GFP plasmid mixed with red fluorescent
eads and sacrificed 3 days later for determination of localiza-
ion of GFP transfection in relation to the site of IM injections.
issue for immunohistochemistry and reverse transcriptase–
olymerase chain reaction was obtained from the remaining
ats’ ischemic and nonischemic hind limbs.
tatistical methods. All data are expressed as mean  SD.
omparisons between groups at multiple stages were per-
ormed by 2-way analysis of variance; if significant, Bonfer-
oni correction for multiple comparisons was applied when
ost-hoc analysis between different time points or between
ifferent groups at the same time point was performed
GraphPad Prism version 5.0a, GraphPad Software Inc., La lolla, California). Statistical significance between 2 groups
as determined by 2-tailed unpaired t tests. Differences
ere considered significant at p  0.05 (2-sided).
esults
omparison of transgene expression. Real-time reverse
ranscriptase–polymerase chain reaction data for exogenous
EGF165/GFP messenger RNA at various time points after
elivery are shown in Figure 1. Using specific primers,
obust exogenous transgene expression (normalized to the
ontralateral nonischemic muscle) was detected in both IM-
nd UM-treated ischemic muscles and was undetectable in
ontrol untreated animals. For both treatment groups,
ransfection was greatest at day 3 following delivery (day 17
fter ligation), decreasing over time. The IM delivery
esulted in significantly greater transfection compared with
he UM delivery at all early time points, with transgene
xpression diminishing in both treatment groups by week 8
Fig. 1).
uscle perfusion and vascular density. At 2 weeks after
liac artery ligation, immediately before gene delivery, mean
BV and MBF in the ischemic leg was reduced to 35%
f the normal leg in all 3 groups (Fig. 2). In the control
roup, there was no change in normalized MBV and MBF
ver time (Fig. 2). With IM therapy, there was a significant
ncrease in normalized MBV that began at day 17 following
igation, reaching a plateau at days 21 and 28, and waning
y week 8. Whereas MBV increased early in IM-treated
schemic muscle, significant increases in MBF were not seen
ntil day 28. In comparison, the improvement in perfusion
ith UM therapy was more delayed, with normalized MBV
nd MBF peaking at 28 days after ligation (14 days
ollowing gene delivery), and persisting to 8 weeks after
day 17 day 21 day 28 week 8
0
2000
4000
6000
Figure 1 Exogenous VEGF165/GFP
mRNA Transcript Following Ligation
Real-time reverse transcriptase–polymerase chain reaction data showing exoge-
nous vascular endothelial growth factor-165 (VEGF165)/green fluorescent pro-
tein (GFP) messenger ribonucleic acid (mRNA) transcript at days 17, 21, and
28 and week 8 after ligation (intramuscular [IM] gene therapy in solid bars,
ultrasound-mediated [UM] therapy in open bars). Relative VEGF165/GFP mRNA
expression was significantly lower for UM delivery compared with IM delivery at
all time points after delivery. *p  0.05 compared with IM gene therapy.igation (Fig. 2). When compared with IM therapy, UM
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Ultrasound-Mediated Versus IM Gene Delivery for Angiogenesis October 27, 2009:1735–42herapy yielded a significantly greater improvement in nor-
alized MBF than with IM therapy. This superior thera-
eutic effect of UM gene delivery was seen at 28 days after
igation and persisted out to week 8 (Fig. 2). Fluorescent
icroangiography analysis revealed reduced vessel density in
he control group’s ischemic muscle 4 weeks after iliac artery
igation. Consistent with CEU perfusion data, at 14 days
fter gene delivery, there were increases in vessel density
oth in the IM and UM groups that mirrored changes in
BV. Whereas changes in MBF at day 28 were signifi-
antly greater for UM, as compared with IM, therapy,
hanges in both MBV and vessel density by FMA at day 28
Figure 2 MBV and MBF in the Ischemic Muscle for 3 Treatmen
(A) Normalized microvascular blood volume (MBV) in the ischemic muscle for the
after ligation. *p  0.005 compared with corresponding data in control untreated
0.001 compared with corresponding baseline (pre-delivery) data. (B) Normalized m
baseline (pre-treatment) and at days 17, 21, and 28 and week 8 after ligation. *p
compared with corresponding data in IM-treated animals; ‡p  0.05 compared wietween UM- and IM-treated animals were not signifi-
antly different (Figs. 2 and 3).
ocalization of gene transfection. There was no discern-
ble GFP signal detected in the ischemic muscle of the
ntreated control group. In comparison, a robust GFP
ignal was detected in both IM- and UM-treated groups by
uorescent confocal microscopy. Whereas IM gene delivery
esulted in focal regions of bright GFP signal predominantly
ithin regions adjacent to IM injection sites, UM-treated
uscle showed a more diffuse signal with a significantly
reater number of microscopic fields expressing GFP (Fig. 4).
or IM delivery, immunohistochemical staining revealed focal
ups
ment groups at baseline (pre-treatment) and days 17, 21, and 28 and week 8
ls, †p  0.05 compared with corresponding data in IM-treated animals, ‡p 
scular blood flow (MBF) in the ischemic muscle for the 3 treatment groups at
1 compared with corresponding data in control untreated animals; †p  0.005
esponding baseline (pre-delivery) data. Abbreviations as in Figure 1.t Gro
3 treat
anima
icrova
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October 27, 2009:1735–42 Ultrasound-Mediated Versus IM Gene Delivery for Angiogenesisreas of colocalization of GFP predominantly within myocytes,
ith some signal from surrounding capillaries and interstitial
ells of the ischemic adductor muscle (Fig. 5) and little to no
ignal from arterioles or venules. In UM-treated muscle, the
FP signal was predominantly associated with the vascular
ndothelium of small- and medium-sized arterioles within the
schemic adductor muscle, with signal also detected within
apillaries and extending to surrounding myocytes (Fig. 5).
iscussion
urrently, the most effective strategy for delivering angio-
enic genes to induce clinically important therapeutic neo-
ascularization within ischemic muscle is unknown. We
ave previously demonstrated the potential of UM destruc-
ion of VEGF165 plasmid-bearing microbubbles for improv-
ng tissue perfusion in the setting of severe chronic hind-
imb ischemia (9). The aim of our present study was to
irectly compare this noninvasive technique for gene deliv-
ry to the current standard delivery method of direct IM
njection. We have now demonstrated that despite lower
A B
D E
G
Figure 3 Microvessel Density by FMA in 3 Groups
(A to F) Representative stacked images of microvessels in ischemic hind-limb mu
cleic acid, using fluorescent microangiography (FMA). Scale bar  50 m. (G) Qua
8 following ligation, in all groups. At day 28 after ligation, FMA revealed a significa
UM-treated animals, as compared with control untreated animals, with a trend for
sponding data from control ischemic muscle. Abbreviations as in Figure 1.otal transfection, the strategy of UM gene delivery pro-
uces a pattern of gene expression that may be more
fficacious compared with direct intramuscular injections for
he induction of therapeutic angiogenesis in ischemic skel-
tal muscle. This finding could potentially lead to the
evelopment of newer, more effective and noninvasive
ethods of gene delivery for therapeutic angiogenesis in
atients, one that could be used to test multiple and
epetitive gene therapies in clinical trials.
ene delivery strategies for angiogenesis. Initial strate-
ies for transcatheter delivery of angiogenic genes have used
n intracoronary route, which is limited by imprecise local-
zation of genes and the potential for systemic delivery to
oncardiac tissue. In addition, transfection efficiency is poor
10), in part due to poor retention and rapid clearance by
irculating deoxyribonucleases. For this reason, catheter-
ased techniques for transendocardial injections have been
eveloped (11), and along with intraoperative direct IM
njections (12), have become the preferred delivery tech-
ique. Whereas IM delivery has advantages including the
C
F
ter no treatment and IM and UM delivery of VEGF165/GFP plasmid deoxyribonu-
ve microvessel density by FMA of ischemic hind-limb muscle at day 28 and week
ease in the density of microvessels in the ischemic leg of both IM- and
r vessel density in UM-treated ischemic muscle. *p  0.05 compared with corre-scle af
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Ultrasound-Mediated Versus IM Gene Delivery for Angiogenesis October 27, 2009:1735–42elivery of most of the genetic material directly into target
issue with minimal systemic effects, this method is invasive,
specially as it pertains to cardiac delivery. Even though the
isk of serious complications is relatively low (11), repeated
eliveries have not been studied in clinical trials and will
emain a limitation of this technique.
A noninvasive strategy for gene delivery by the ultrasonic
estruction of plasmid-bearing microbubbles has been de-
eloped that results in targeted transfection and therapeutic
ffects in many tissues, including skeletal and cardiac mus-
le, without delivery to remote nontargeted organs. If
ffective and safe, such a strategy could become the tech-
ique of choice for repeated gene deliveries to any organ
ccessible to ultrasound. Only a few studies have compared
he efficacy of UM gene delivery to standard direct IM
njection. Christiansen et al. (7) compared the efficacy of
ltrasonic destruction of intravenous or intra-arterial injec-
ions of luciferase-reporter plasmid DNA-bound micro-
ubbles to direct IM injections into normal skeletal muscle.
hereas luciferase activity was similar between animals
reated with IM and intra-arterial microbubble delivery,
hey found 100-fold greater luciferase activity in skeletal
uscle with IM delivery, as compared with intravenous UM
elivery. Similarly Pislaru et al. (13) demonstrated similar
A
C
Figure 4 Transgene Expression After IM Delivery
Focality of transgene expression after IM delivery. The IM injection sites were mar
assessed in adjacent fields at day 3 following injection. Strong GFP signal is seen
distance from the needle tract. Remote hind-limb muscle is shown in B where the
25) positive for GFP signal in IM- and UM-treated ischemic skeletal muscle. *p  0.0
ultrasound; other abbreviations as in Figure 1.uciferase activity in rat skeletal muscle treated with IM ilasmid compared with intra-arterial UM delivery; however,
hey did not assess intravenous UM delivery.
Our study is the first to directly compare IM delivery to
M destruction of plasmid DNA-bearing microbubbles,
sing a “functional” gene, namely VEGF165. At first glance,
t does not seem a fair comparison, with transfection
fficiency by real-time polymerase chain reaction demon-
trating an 8- to 10-fold greater messenger RNA expression
or IM delivery as compared with intravenous UM delivery.
he magnitude of the difference is similar to that published
ith reporter genes. This is not surprising given the large
iscrepancy in total DNA dose delivered, with nearly 100%
elivered for IM injection compared with a much lesser
raction for UM delivery. Ultrasound-mediated delivery is a
ethod of targeted intravascular gene delivery that is reliant
ntirely on local tissue perfusion, whereby transfection is
argeted to the vascular endothelium and adjacent perivas-
ular tissues by external ultrasound application. Whereas
00% of the DNA is administered intravenously, due to low
lood flow in noncontracting skeletal muscle coupled with
arked flow reduction due to iliac artery ligation, only a
mall fraction, 10%, will enter the ischemic hind limb
here it can be delivered. To maximize delivery, we used
onger pulsing intervals to allow microbubble replenishment
B
th fluorescent microspheres (A, single white arrow) and GFP expression
se proximity to injection sites (A, double white arrows), declining with increasing
inimal GFP expression. C shows the number of high power (20) fields (out of
pared with corresponding data from IM-treated muscle. IV  intravenous; U/S ked wi
in clo
re is m
5 comnto tissue between destructive ultrasound pulses, a high
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October 27, 2009:1735–42 Ultrasound-Mediated Versus IM Gene Delivery for Angiogenesiscoustic power and low frequency (14), and prolonged the
ltrasound delivery time. Using a continuous infusion of
NA-bearing microbubbles, a steady local concentration
ithin the vascular bed is maintained, and repeated appli-
ation of intermittent high-power ultrasound during the
nfusion allows for continuous gene delivery as the micro-
ubbles recirculate through the systemic circulation. By
canning along the length of the hind-limb adductor mus-
les, we were able to deliver plasmid DNA to the entire
roximal ischemic bed, resulting in a wider field of delivery.
inally, by continuing ultrasonic destruction for 10 min after
ompletion of microbubble-DNA infusion, we allowed
dditional delivery of any remaining circulating DNA-
earing microbubbles that had not been delivered.
ocalization of gene transfection: importance for angio-
enesis. Despite substantially lower transgene expression,
M delivery resulted in a similar angiogenic effect, by both
EU perfusion imaging and by fluorescent microangiogra-
hy. Changes in microvascular blood volume were noted
arlier with IM gene therapy, suggesting a more rapid onset of
A
B
C
Figure 5 Immunofluorescent Staining of IM- and UM-Treated Is
Examples of immunofluorescent staining of IM-treated (A to C) and UM-treated (D
staining (TO-PRO-3); yellow  colocalization of GFP and red CD31 staining. Within
arrows), interspersed with regions of strong GFP signal localized predominantly wi
within arterioles (C, red arrows). In comparison, within UM-treated muscle, a more
(D, yellow arrows), their surrounding myocytes (E, white arrows), and within sma
Figure 1.ngiogenesis in keeping with substantially greater VEGF aransgene expression. However, although maximal changes in
essel density by FMA and MBV by CEU were similar
n both IM- and UM-treated ischemic muscle, the increase
n MBF, arguably a more functional end point, was greater
or UM gene therapy. The discordance between marked
ncreases in MBV and more modest changes in MBF in
M-treated ischemic muscle bears similarity to the neovas-
ulature within highly vascularized tumors, whereby CEU
lood volume is greater than surrounding normal tissue;
owever, due to immature and tortuous vessels, blood
elocity is low leading to proportionately lower MBF
15,16). This novel observation suggests that UM delivery
ay have a greater “biologic” response than IM delivery,
esulting in a more functional neovasculature despite lower
ransfection rates. The use of a bicistronic vector encoding
or VEGF165 and a marker gene, enhanced GFP, allowed us
o compare the localization of gene transfection by both
M and IM delivery. Ultrasound-mediated gene therapy
roduced a more diffuse pattern of transfection and was
ocalized to the vascular endothelium of medium to small
ic Muscle
ischemic muscle, at day 17 after ligation. Red  CD31 staining; blue  nuclear
ated muscle, there were areas without discernable GFP signal (A, yellow
yocytes (B, white arrows) and surrounding capillaries, with little GFP signal
e GFP signal was seen, localized to the vascular endothelium of both capillaries
edium-sized arterioles (F, red arrows). Scale bar  50 m. Abbreviations as inD
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Ultrasound-Mediated Versus IM Gene Delivery for Angiogenesis October 27, 2009:1735–42ikely via the surrounding microvasculature. In contrast, IM
elivery resulted in more focal pockets of transfection, inter-
persed with areas of no transfection. Areas of highest trans-
ection were localized to IM injection sites, with a decreasing
radient of transfection with distance from the needle track.
he GFP/VEGF transfection was localized predominantly to
yocytes, along with adjacent capillaries, with minimal to no
rteriolar transfection. The latter finding is in keeping with
ata from Gal et al. (17), who used in situ hybridization to
how that myocytes represented the site of luciferase expression
fter IM injections of firefly luciferase-reporter gene into
keletal muscle in rabbits. Thus, our study demonstrates that a
trategy of intravascular gene therapy that enhances transfec-
ion to the vascular endothelium of arterioles and capillaries in
wider, more diffuse pattern is more effective than one that
redominantly targets myocytes, along with adjacent capillar-
es, in a more focal distribution.
tudy limitations. For controls, we only studied animals
hat received no treatment. Ideally, controls should also
nclude groups with: 1) ultrasound alone at the same
osimetry; 2) microbubbles bearing VEGF165 plasmid
NA alone; and 3) ultrasound and microbubbles bearing
ontrol plasmid DNA. We have previously demonstrated that
M delivery of microbubbles bearing GFP plasmid DNA as a
icrobubble-control plasmid DNA treated group yielded no
ignificant improvement in MBF over time and was similar to
ontrol animals that received no treatment (9).
onclusions
n summary, despite lower transgene expression, UM mi-
robubble destruction of VEGF165 may be more effective
han direct IM delivery. Ultrasound-mediated delivery re-
ults in directed vascular transfection over a wider distribu-
ion as compared with IM delivery, which predominantly
ransfects myocytes and surrounding capillaries. This differ-
nce in the localization of gene transfection likely accounts
or the more efficient angiogenesis seen with UM delivery of
NA-bearing microbubbles and highlights the importance
f the site of transfection in optimizing gene delivery
trategies for therapeutic angiogenesis.
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